HealthPolitics

Opinion: Cancer vaccines are finally here. How do we get them to patients?

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/10/2026, 08:36:25 UTC.

Briefings

A Phase 3 study at the European Society for Medical Oncology Congress reported that the cancer vaccine intismeran autogene reduced recurrence or death risk by 42% compared to pembrolizumab alone. This is the first neoantigen and mRNA therapy to meet its Phase 3 endpoint in oncology, marking a significant milestone for personalized cancer vaccines despite the ongoing challenge of accelerating development and increasing patient access.

Key points

• A Phase 3 study at the European Society for Medical Oncology Congress reported that the cancer vaccine intismeran autogene reduced recurrence or death risk by 42% compared to pembrolizumab alone.
• This is the first neoantigen and mRNA therapy to meet its Phase 3 endpoint in oncology, marking a significant milestone for personalized cancer vaccines despite the ongoing challenge of accelerating development and increasing patient access.

Context

The evidence comes from a report presented at the annual European Society for Medical Oncology Congress, where a Phase 3 study compared intismeran autogene to pembrolizumab (Keytruda). The study is part of a collection of well-conducted studies showing promise for cancer therapeutic vaccines, though the specific city or country of the congress is not mentioned in the source.

Limitations

The evidence is limited to a single Phase 3 study at an unspecified congress location. The source does not provide details on the specific date of the study, the number of patients enrolled, or the specific geographic region where the congress took place. The findings represent a milestone but do not address the broader challenges of accelerating development and increasing patient access.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/10/2026, 10:19:50 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeif44xmvhfw5slcdz57irc2xafkumw7slhe5klaj7e46pdnp545kxm